The pathogenicity of culprit antibody in autoimmune encephalitis

doi:10.3969/j.issn.1672-6731.2022.01.001

Abstract

Abstract: Autoimmune encephalitis (AE) comprises an important group of autoimmune diseases targeting central nervous system. Although the growing number of new antibodies has amplified our understanding of the disease spectrum of AE, it has also produced challenges to accurately recognize the clinical phenotypes. Culprit antibody refers to the pathogenic antibody causing one or more clinical phenotypes during the disease. This concept establishes a connection between autoantibodies and clinical phenotypes, and also reflects the idea of modern precision medicine. The most important for better understanding the antibody - phenotype causality is to ascertain the pathogenicity of culprit antibody. Accordingly, we will discuss the recent progress in pathogenesis of the culprit antibody in AE.

Key words: Encephalitis, Autoimmune diseases, Antibodies, Virulence, Review

摘要： 自身免疫性脑炎是一种中枢神经系统自身免疫性疾病，大量新抗体的发现扩增其临床疾病谱，但也为临床表型的精准识别带来一定困难。责任抗体系指同一例患者病程中与一个或多个临床表型有对应因果关系的致病性抗体，这一概念的提出，在自身抗体与临床表型之间建立联系，体现出现代精准医学的理念。明确责任抗体的致病性是理解抗体?临床表型因果关系模式的重中之重。本文总结自身免疫性脑炎责任抗体致病机制研究进展。

关键词: 脑炎, 自身免疫疾病, 抗体, 毒力, 综述

CHEN Sheng, ZHANG Yi-zongheng, SHEN Ding-ding, ZHOU Qin-ming. The pathogenicity of culprit antibody in autoimmune encephalitis[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(1): 1-7.

陈晟, 张仪纵横, 沈丁玎, 周勤明. 论自身免疫性脑炎责任抗体的致病性[J]. 中国现代神经疾病杂志, 2022, 22(1): 1-7.

/ / Recommend / Download Citations

URL: http://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2022.01.001

http://journal11.magtechjournal.com/cjcnn/EN/Y2022/V22/I1/1

References

[1] Haselmann H, Mannara F, Werner C, Planagumà J, Miguez-Cabello F, Schmidl L, Grünewald B, Petit-Pedrol M, Kirmse K, Classen J, Demir F, Klöcker N, Soto D, Doose S, Dalmau J, Hallermann S, Geis C. Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction[J]. Neuron, 2018, 100: 91-105.
[2] Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system[J]. Physiol Rev, 2017, 97: 839-887.
[3] Goodfellow JA, Mackay GA. Autoimmune encephalitis[J]. J R Coll Physicians Edinb, 2019, 49: 287-294.
[4] Giannoccaro MP, Wright SK, Vincent A. In vivo mechanisms of antibody-mediated neurological disorders: animal models and potential implications[J]. Front Neurol, 2020, 10: 1394.
[5] Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes[J]. J Neurol Neurosurg Psychiatry, 2018, 89: 526-534.
[6] Nikolaus M, Kreye J, Turko P, Vida I, Knierim E, Prüss H. CSF reactivity in GABAA receptor antibody encephalitis-immunocytochemical distribution in the murine brain[J]. Brain Res, 2019, 1704: 249-256.
[7] Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, McCracken L, Martinez-Hernandez E, Mason WP, Kruer MC, Ritacco DG, Grisold W, Meaney BF, Alcalá C, Sillevis-Smitt P, Titulaer MJ, Balice-Gordon R, Graus F, Dalmau J. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies[J]. Lancet Neurol, 2014, 13: 276-286.
[8] Zhou Q, Zhu X, Meng H, Zhang M, Chen S. Anti-dipeptidyl-peptidase-like protein 6 encephalitis, a rare cause of reversible rapid progressive dementia and insomnia[J]. J Neuroimmunol, 2020, 339: 577114.
[9] Chen XJ, Li HF, Qiu W, Xu Y, Chen S. Neuroimmune diseases and responsible antibodies[J]. Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021, 28: 283-287. 陈向军, 李海峰, 邱伟, 徐雁, 陈晟. 神经免疫疾病与责任抗体[J]. 中国神经免疫学和神经病学杂志, 2021, 28: 283-287.
[10] Gómez-Pinedo U, García-Ávila Y, Gallego-Villarejo L, Matías-Guiu JA, Benito-Martín MS, Esteban-García N, Sanclemente-Alamán I, Pytel V, Moreno-Jiménez L, Sancho-Bielsa F, Vidorreta-Ballesteros L, Montero-Escribano P, Matías-Guiu J. Sera from patients with NMOSD reduce the differentiation capacity of precursor cells in the central nervous system[J]. Int J Mol Sci, 2021, 22: 5192.
[11] Huang YQ, Xiong H. Anti-NMDA receptor encephalitis: a review of mechanistic studies[J]. Int J Physiol Pathophysiol Pharmacol, 2021, 13: 1-11.
[12] Ding J, Li X, Tian Z. Clinical features of coexisting anti-NMDAR and MOG antibody-associated encephalitis: a systematic review and meta-analysis[J]. Front Neurol, 2021, 12: 711376.
[13] Mitoma H, Honnorat J, Yamaguchi K, Manto M. Fundamental mechanisms of autoantibody-induced impairments on ion channels and synapses in immune-mediated cerebellar ataxias[J]. Int J Mol Sci, 2020, 21: 4936.
[14] Mandel-Brehm C, Dubey D, Kryzer TJ, O'Donovan BD, Tran B, Vazquez SE, Sample HA, Zorn KC, Khan LM, Bledsoe IO, McKeon A, Pleasure SJ, Lennon VA, DeRisi JL, Wilson MR, Pittock SJ. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis[J]. N Engl J Med, 2019, 381: 47-54.
[15] Ni Y, Shen D, Zhang Y, Song Y, Gao Y, Zhou Q, He L, Yin D, Wang Y, Song F, Chen M, Lian Y, Chen Y, Zhao X, Zhang X, Chen X, Wang Y, Zhang L, Mo N, Lv D, Liu J, Mao Z, Peng L, Chen S. Expanding the clinical spectrum of anti-IgLON5 disease: a multicenter retrospective study[J]. Eur J Neurol, 2022, 29: 267-276.
[16] Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, Contreras A, Giometto B, Compta Y, Embid C, Vilaseca I, Iranzo A, Santamaría J, Dalmau J, Graus F. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study[J]. Lancet Neurol, 2014, 13: 575-586.
[17] Dubey D, Wilson MR, Clarkson B, Giannini C, Gandhi M, Cheville J, Lennon VA, Eggers S, Devine MF, Mandel-Brehm C, Kryzer T, Hinson SR, Khazaie K, Hales C, Kattah J, Pavelko KD, Andrews P, Eaton JE, Jitprapaikulsan J, Mills JR, Flanagan EP, Zekeridou A, Leibovich B, Fryer J, Torre M, Kaufman C, Thoreson JB, Sagen J, Linnoila JJ, DeRisi JL, Howe CL, McKeon A, Pittock SJ. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis[J]. JAMA Neurol, 2020, 77: 1420-1429.
[18] Landa J, Guasp M, Míguez-Cabello F, Guimarães J, Mishima T, Oda F, Zipp F, Krajinovic V, Fuhr P, Honnorat J, Titulaer M, Simabukuro M, Planagumà J, Martínez-Hernández E, Armangué T, Saiz A, Gasull X, Soto D, Graus F, Sabater L, Dalmau J; GluK2 Encephalitis Study Group. Encephalitis with autoantibodies against the glutamate kainate receptors GluK2[J]. Ann Neurol, 2021, 90: 101-117.
[19] Lee ST, Lee BJ, Bae JY, Kim YS, Han DH, Shin HS, Kim S, Park DK, Seo SW, Chu K, Lee SK, Ho WK. CaVα2δ autoimmune encephalitis: a novel antibody and its characteristics[J]. Ann Neurol, 2021, 89: 740-752.
[20] Gardoni F, Stanic J, Scheggia D, Benussi A, Borroni B, Di Luca M. NMDA and AMPA receptor autoantibodies in brain disorders: from molecular mechanisms to clinical features[J]. Cells, 2021, 10: 77.
[21] Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models[J]. Lancet Neurol, 2019, 18: 1045-1057.
[22] Bauer J, Bien CG. Neuropathology of autoimmune encephalitides[J]. Handb Clin Neurol, 2016, 133: 107-120.
[23] Ramanathan S, Al-Diwani A, Waters P, Irani SR. The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis[J]. J Neurol, 2021, 268: 1689-1707.
[24] Wright SK, Rosch RE, Wilson MA, Upadhya MA, Dhangar DR, Clarke-Bland C, Wahid TT, Barman S, Goebels N, Kreye J, Prüss H, Jacobson L, Bassett DS, Vincent A, Greenhill SD, Woodhall GL. Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis[J]. Commun Biol, 2021, 4: 1106.
[25] Goi LDS, Altenhofen S, Nabinger DD, Bonan CD, Sato DK. Decreased convulsive threshold and memory loss after anti-NMDAR positive CSF injection in zebrafish[J]. J Neuroimmunol, 2021, 359: 577689.
[26] Peng X, Hughes EG, Moscato EH, Parsons TD, Dalmau J, Balice-Gordon RJ. Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies[J]. Ann Neurol, 2015, 77: 381-398.
[27] Zhang TY, Cai MT, Zheng Y, Lai QL, Shen CH, Qiao S, Zhang YX. Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis: a review[J]. Front Immunol, 2021, 12: 652820.
[28] Scheggia D, Stanic J, Italia M, La Greca F, Zianni E, Benussi A, Borroni B, Di Luca M, Gardoni F. GluA3 autoantibodies induce alterations in dendritic spine and behavior in mice[J]. Brain Behav Immun, 2021. [Epub ahead of print]
[29] Schaefer N, Roemer V, Janzen D, Villmann C. Impaired glycine receptor trafficking in neurological diseases[J]. Front Mol Neurosci, 2018, 11: 291.
[30] Crisp SJ, Dixon CL, Jacobson L, Chabrol E, Irani SR, Leite MI, Leschziner G, Slaght SJ, Vincent A, Kullmann DM. Glycine receptor autoantibodies disrupt inhibitory neurotransmission[J]. Brain, 2019, 142: 3398-3410.
[31] Carvajal-González A, Jacobson L, Clover L, Wickremaratchi M, Shields S, Lang B, Vincent A. Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice[J]. Neuropathol Appl Neurobiol, 2021, 47: 316-327.
[32] Ye F, Fan C, Peng M, Liu S, Yu Y, Yang L. Anti-IgLON5 disease in a pediatric patient with Langerhans cell histiocytosis[J]. Clin Chim Acta, 2021. [Epub ahead of print]
[33] Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome[J]. J Neuroinflammation, 2016, 13: 226.
[34] Landa J, Gaig C, Plagumà J, Saiz A, Antonell A, Sanchez-Valle R, Dalmau J, Graus F, Sabater L. Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration[J]. Ann Neurol, 2020, 88: 1023-1027.
[35] Ryding M, Gamre M, Nissen MS, Nilsson AC, Okarmus J, Poulsen AAE, Meyer M, Blaabjerg M. Neurodegeneration induced by anti-IgLON5 antibodies studied in induced pluripotent stem cell-derived human neurons[J]. Cells, 2021, 10: 837.
[36] Scotton WJ, Karim A, Jacob S. Glutamate receptor antibodies in autoimmune central nervous system disease: basic mechanisms, clinical features, and antibody detection[J]. Methods Mol Biol, 2019, 1941: 225-255.
[37] Guevara C, Farias G, Silva-Rosas C, Alarcon P, Abudinen G, Espinoza J, Caro A, Angus-Leppan H, de Grazia J. Encephalitis associated to metabotropic glutamate receptor 5 (mGluR5) antibodies in cerebrospinal fluid[J]. Front Immunol, 2018, 9: 2568.
[38] Spatola M, Petit Pedrol M, Maudes E, Simabukuro M, Muñiz-Castrillo S, Pinto AL, Wandinger KP, Spiegler J, Schramm P, Dutra LA, Iorio R, Kornblum C, Bien CG, Höftberger R, Leypoldt F, Titulaer MJ, Sillevis Smitt P, Honnorat J, Rosenfeld MR, Graus F, Dalmau J. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis[J]. Neurology, 2020, 95: e3012-3025.
[39] Spatola M, Sabater L, Planagumà J, Martínez-Hernandez E, Armangué T, Prüss H, Iizuka T, Caparó Oblitas RL, Antoine JC, Li R, Heaney N, Tubridy N, Munteis Olivas E, Rosenfeld MR, Graus F, Dalmau J. Encephalitis with mGluR5 antibodies: symptoms and antibody effects[J]. Neurology, 2018, 90: e1964-1972.
[40] Ohkawa T, Satake S, Yokoi N, Miyazaki Y, Ohshita T, Sobue G, Takashima H, Watanabe O, Fukata Y, Fukata M. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis[J]. J Neurosci, 2014, 34: 8151-8163.
[41] Dai X, Kuang L, Feng L, Yi X, Tang W, Liao Q, Long X, Wang J, Li J, Yang H, Xiao B, Li G, Chen S. Anti-dopamine receptor 2 antibody-positive encephalitis in adolescent[J]. Front Neurol, 2020, 11: 471.
[42] Sinmaz N, Tea F, Pilli D, Zou A, Amatoury M, Nguyen T, Merheb V, Ramanathan S, Cooper ST, Dale RC, Brilot F. Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders[J]. Acta Neuropathol Commun, 2016, 4: 126.
[43] Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, Ben-Pazi H, Varadkar S, Aumann TD, Horne MK, Church AJ, Fath T, Brilot F. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders[J]. Brain, 2012, 135(Pt 11): 3453-3468.
[44] Hara M, Ariño H, Petit-Pedrol M, Sabater L, Titulaer MJ, Martinez-Hernandez E, Schreurs MW, Rosenfeld MR, Graus F, Dalmau J. DPPX antibody-associated encephalitis: main syndrome and antibody effects[J]. Neurology, 2017, 88: 1340-1348.
[45] Piepgras J, Höltje M, Michel K, Li Q, Otto C, Drenckhahn C, Probst C, Schemann M, Jarius S, Stöcker W, Balint B, Meinck HM, Buchert R, Dalmau J, Ahnert-Hilger G, Ruprecht K. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons[J]. Neurology, 2015, 85: 890-897.
[46] Yamagata A, Fukai S. Insights into the mechanisms of epilepsy from structural biology of LGI1-ADAM22[J]. Cell Mol Life Sci, 2020, 77: 267-274.
[47] Romoli M, Krashia P, Sen A, Franciotta D, Gastaldi M, Nobili A, Mancini A, Nardi Cesarini E, Nigro P, Tambasco N, Mercuri NB, Parnetti L, Di Filippo M, D'Amelio M, Irani SR, Costa C, Calabresi P. Hippocampal epileptogenesis in autoimmune encephalitis[J]. Ann Clin Transl Neurol, 2019, 6: 2261-2269.
[48] Ramberger M, Berretta A, Tan JMM, Sun B, Michael S, Yeo T, Theorell J, Bashford-Rogers R, Paneva S, O'Dowd V, Dedi N, Topia S, Griffin R, Ramirez-Franco J, El Far O, Baulac S, Leite MI, Sen A, Jeans A, McMillan D, Marshall D, Anthony D, Lightwood D, Waters P, Irani SR. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms[J]. Brain, 2020, 143: 1731-1745.
[49] Qiao J, Zhao X, Wang S, Li A, Wang Z, Cao C, Wang Q. Functional and structural brain alterations in encephalitis with LGI1 antibodies[J]. Front Neurosci, 2020, 14: 304.
[50] Miller TD, Chong TT, Aimola Davies AM, Ng TWC, Johnson MR, Irani SR, Vincent A, Husain M, Jacob S, Maddison P, Kennard C, Gowland PA, Rosenthal CR. Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis[J]. Brain, 2017, 140: 1212-1219.
[51] Patterson KR, Dalmau J, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia[J]. Ann Neurol, 2018, 83: 40-51.
[52] Fernandes D, Santos SD, Coutinho E, Whitt JL, Beltrão N, Rondão T, Leite MI, Buckley C, Lee HK, Carvalho AL. Disrupted AMPA receptor function upon genetic-or antibody-mediated loss of autism-associated CASPR2[J]. Cereb Cortex, 2019, 29: 4919-4931.
[53] Nibber A, Mann EO, Pettingill P, Waters P, Irani SR, Kullmann DM, Vincent A, Lang B. Pathogenic potential of antibodies to the GABA B receptor[J]. Epilepsia Open, 2017, 2: 355-359.
[54] McKay JH, Dimberg EL, Lopez Chiriboga AS. A systematic review of Gamma-aminobutyric acid receptor type B autoimmunity[J]. Neurol Neurochir Pol, 2019, 53: 1-7.
[55] Nieto A, Bailey T, Kaczanowska K, McDonald P. GABA(B) receptor chemistry and pharmacology: agonists, antagonists, and allosteric modulators[J]. Curr Top Behav Neurosci, 2021. [Epub ahead of print]
[56] Zhu F, Shan W, Lv R, Li Z, Wang Q. Clinical characteristics of anti-GABA-B receptor encephalitis[J]. Front Neurol, 2020, 11: 403.
[57] Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders-insights and challenges[J]. Nat Rev Neurol, 2020, 16: 353-365.
[58] Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, Gadoth A, Naddaf E, McKeon A, Pittock SJ, Zalewski NL. Clinical spectrum of high-titre GAD65 antibodies[J]. J Neurol Neurosurg Psychiatry, 2021. [Epub ahead of print]
[59] Werner C, Pauli M, Doose S, Weishaupt A, Haselmann H, Grünewald B, Sauer M, Heckmann M, Toyka KV, Asan E, Sommer C, Geis C. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition[J]. Brain, 2016, 139(Pt 2): 365-379.
[60] Geis C, Weishaupt A, Hallermann S, Grünewald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, Boettger MK, Üçeyler N, Fouquet W, Gerlach M, Meinck HM, Sirén AL, Sigrist SJ, Toyka KV, Heckmann M, Sommer C. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition[J]. Brain, 2010, 133: 3166-3180.

Please choose a citation manager

Content to export